Avadel PharmaceuticalsAVDL
13F holders, Q1 2025 (March 31)3holders
0new positions
0sold out
$7.83avg. 13F price*
At the end of Q1 2025, 3 institutions reported holding Avadel Pharmaceuticals plc (AVDL) in their 13F filings, unchanged from Q4 2024. 0 opened new positions and 0 sold out. The largest holders were Knoll Capital Management, LLC ($4.7M), Schulhoff & Co. Inc. ($1.1M) and Huntington National Bank ($16).
- Company
- Avadel Pharmaceuticals plc
- CUSIP
- 05337M104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 500 shares bought, net +500 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Knoll Capital Management, LLC | 3.06% | No change | 600,000 | $4.7M |
| Schulhoff & Co. Inc. | 0.48% | Add +0.4% | 137,500 | $1.1M |
| Huntington National Bank | 0.00% | No change | 1 | $16 |
"% of holder's portfolio" is AVDL's weight in each manager's 13F, not the share of Avadel Pharmaceuticals plc the manager owns.